Compass Therapeutics (CMPX) Return on Capital Employed (2023 - 2025)
Historic Return on Capital Employed for Compass Therapeutics (CMPX) over the last 3 years, with Q3 2025 value amounting to 0.44%.
- Compass Therapeutics' Return on Capital Employed fell 700.0% to 0.44% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.44%, marking a year-over-year decrease of 700.0%. This contributed to the annual value of 0.41% for FY2024, which is N/A changed from last year.
- According to the latest figures from Q3 2025, Compass Therapeutics' Return on Capital Employed is 0.44%, which was down 700.0% from 0.62% recorded in Q2 2025.
- In the past 5 years, Compass Therapeutics' Return on Capital Employed ranged from a high of 0.32% in Q4 2023 and a low of 0.62% during Q2 2025
- Its 3-year average for Return on Capital Employed is 0.42%, with a median of 0.4% in 2024.
- The largest annual percentage gain for Compass Therapeutics' Return on Capital Employed in the last 5 years was -700bps (2025), contrasted with its biggest fall of -2500bps (2025).
- Compass Therapeutics' Return on Capital Employed (Quarter) stood at 0.32% in 2023, then fell by -29bps to 0.42% in 2024, then decreased by -6bps to 0.44% in 2025.
- Its last three reported values are 0.44% in Q3 2025, 0.62% for Q2 2025, and 0.51% during Q1 2025.